Douglas A. Treco - Apr 1, 2024 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
CEO, Director
Signature
/s/ Douglas A Treco
Stock symbol
INZY
Transactions as of
Apr 1, 2024
Transactions value $
-$52,210
Form type
4
Date filed
4/3/2024, 05:23 PM
Previous filing
Mar 15, 2024
Next filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Options Exercise +25K +784.19% 28.2K Apr 1, 2024 Direct F1, F2
transaction INZY Common Stock Sale -$52.2K -7.52K -26.69% $6.94 20.7K Apr 2, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Restricted Stock Units Options Exercise $0 -25K -25% $0.00 75K Apr 1, 2024 Common Stock 25K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
F2 Includes 3,188 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 28, 2024.
F3 This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date.